REGISTERED LETTER – RETURN RECEIPT REQUESTED

Re : Formal notice sent by FedEx

To the CEO of BankBoston

Dear Sir,

Fifteen years of inquiries and international investigations have elicited various answers and results, tending through all channels to indicate yourself as point of origin.

We recapitulate for you:

On October 22, 1997, you signed a contract between Biosite Inc. and BankBoston and its partners. This was a ten-year contract expiring on October 22, 2007, with a stolen patent suddenly and inexplicably presented to Biosite so that BankBoston received the grand honor of distributing, through Biosite, an extremely significant patented innovation stolen from Nogdan of Israel. The contract concerns a patented innovation of great import, unique in the world, which can isolate any protein at all from the genome a million times better, in terms of quantity, than any other of the world’s most modern technologies, and thus can produce human antibodies in a very short time, amounting to an hour or two instead of the 6 to 14 months required by the hybridoma method. The latter, invented by the founder of Biosite himself, Howard Greene, provides very expensive and unstable human antibodies, vulnerable to protein cross-reactions that consign the whole effort to the trash bin, but in the entire world there had been no other method.

This new, revolutionary patent, unique in the world, using blood and not inside the cell like the molecular technique, is US Patent no. 5,869,409, applied for in August 1993 and issued February 9, 1999. It happens that for this patent, with Ms. Rivka Zusman as inventor, all marketing and development rights were already assigned by Rivka Zusman on February 15, 1994, to Nogdan Immunochemicals Ltd. of Gilo, Jerusalem, consisting of four partners: the Zusman couple holding 50% and I, Roland Taieb, together with my wife Sarah Shoval, the other 50%. By this contract, complete global exclusivity in marketing belongs to Mr. Roland Taieb, i.e. to myself, with validity even confirmed, as of May 29, 2000, by the Supreme Court of Israel (whose irreversible decision I attach for you) as well as by a further legal decision, of November 19, 1998, which is very harsh and severe regarding any company dealing with the patented Nogdan innovation without the prior written consent of Mr. Roland Taieb.

Starting in September 1995, the Zusmans, together with their attorney Yair Green, met with Howard Greene of Biosite, a small company of no great value, traded on the Second Marché and selling an apparatus for detecting the level of swallowed or injected drugs. Nothing more! It happens that the Abbott company, of the USA, filed a complaint against Biosite for stealing the patent, on the grounds that the patent belongs to Abbott and was stolen from them by Biosite. Biosite paid $5.5 million in order to continue operations rather than close its doors. This is on record throughout Biosite. However, Biosite, the co-inventor of the hybridoma method, immediately licensed to others, for two years as of September 22, 1995, the patent stolen from Nogdan. Because the first results were so unique globally, Biosite had itself registered on NASDAQ as of February 12, 1997, and it was very well received on the market.

At the same time, since 1996, years of clinical trials were under way for Medarex Inc. and its transgenic mice. The trials all succeeded, as the mice provided human antibodies at a level of 100%, whereas Medarex had previously never exceeded 85% and thus had achieved nothing of value for medicines, vaccines, etc. On December 1, 1999, Biosite and Medarex quietly filed for a patent under which, using the extraordinary capabilities of the patent stolen from Nogdan, the mice would provide human antibodies at a level of 100% and thus change the face of the new medicine. The announcement was made worldwide through the media on December 6, 1999, and immediately Medarex exploded upward on NASDAQ by 3500% — absolutely unique in NASDAQ history! But Medarex was thoroughly concealing its Biosite connection and the stolen patent. It did not announce its collaboration with Biosite until June 1, 2000 (or two days after the Israeli Supreme Court’s decision!), which was six months after the successful murine experiments, so that the gigantic commercial success of Medarex and Abgenix would not have the stolen Nogdan patent as its one and only progenitor.

Medarex immediately lined up Abgenix (and subsequently Pfizer) to create a duopoly rather than retain a monopoly forbidden by American law, and it collected $39.7 million for being one of the world’s only two exploiters of a unique, but stolen, patent.

Then suddenly on October 22, 1997, BankBoston and its partners signed a ten-year contract with Biosite so that Biosite, with no explanation whatever, suddenly became the licensee of the patent stolen from Nogdan. Immediately on learning this, Johnson & Johnson acquired Biosite. We are demanding 3 thousand million dollars per year in indemnification from Biosite for their use of the stolen patent. The sum for the fourteen years between 1996 and 2010 is 42 thousand million dollars, but that is what they bought into. (A copy of their letter is attached.)

Moreover, more than 1200 laboratories around the world are using the stolen Nogdan patent and prospering enormously. All these companies have been warned via FedEx at least twice.

As of the start of August 2010, entire teams of attorneys will be doing everything possible to recover damages, with interest, from every company, and never less than 50% of their 2007 turnover.

More significant yet : In December 2004, Biosite notified us, in a registered letter — absolute proof — from the Biosite director-general of intellectual property, that they were the owners of prior art for this patent and that they were prepared to have the patent, which they had stolen from Nogdan, annulled! (His harsh but absurd letter is attached.) Admitting, beyond a possible doubt, that they were working with the stolen patent, they claim that it is theirs by virtue of prior art beginning in 1995. Our patent was filed for in August 1993, rendering their case hopeless.

For BankBoston, matters are more serious a thousandfold, because you and your partners are the largest American banks and it is neither admissible nor excusable that someone has cheated and misled you. Following are my two prescriptions, according to which I may or may not reduce my extremely firm demand for damages and interest amounting to $75 thousand million.

1) Explain, if you can, how such a patent, belonging to Nogdan, would be in your possession since 1997, when the patent was assigned its number only on February 9, 1999, so that in 1997 it was still held secret in the vaults of the US Patent Office.

2) Please provide me a list of the companies that signed for the patent with you, and a copy of the contracts.

In addition:

3) What is the exact role of Wellington and of Kopp? What about their millions of blocked shares? What are they doing, and on what authority?

4) If you refuse to cooperate, I promise I will have everything in your banks, and all your property, confiscated against the debt to us.

5) If you show good will, then the sum will be reduced in accordance with your good will because at least proof will exist that for your own part, you were also cheated.

I repeat that only ten days are allotted to you. We have lost too much of our time and money — from 1995 to 2010 is fifteen years — and we refuse to pointlessly lose more.

I await your prompt reply.

Roland TAIEB
22 Zalman Shazar St., Ramat Poleg, tel : 972-9-8850635, fax : 972-9-8850685, cell : 972-522-516153